Page last updated: 2024-10-24

verapamil and Eosinophilia

verapamil has been researched along with Eosinophilia in 2 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Eosinophilia: Abnormal increase of EOSINOPHILS in the blood, tissues or organs.

Research Excerpts

Excerpt	Relevance	Reference
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation."	7.78	Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012)
"Verapamil is a useful drug with therapeutic targeting on GCH and a potential way to limit mucous production and improve bronchial inflammation."	3.78	Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. ( Ghafarzadegan, K; Hadi, R; Khakzad, MR; Meshkat, M; Mirsadraee, M; Mohammadpour, A; Saghari, M, 2012)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Menciu, C	1
Duflos, M	1
Fouchard, F	1
Le Baut, G	1
Emig, P	1
Achterrath, U	1
Szelenyi, I	1
Nickel, B	1
Schmidt, J	1
Kutscher, B	1
Günther, E	1
Khakzad, MR	1
Mirsadraee, M	1
Mohammadpour, A	1
Ghafarzadegan, K	1
Hadi, R	1
Saghari, M	1
Meshkat, M	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps[NCT03102190]	Phase 1	6 participants (Actual)	Interventional	2017-06-05	Terminated (stopped due to Phase II funding not available)
Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis[NCT02454608]		29 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to Evidence that the dose is insufficient.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Dose Limiting Toxicity

Dose Limiting Toxicity will be defined as a development of 2nd or 3rd degree heart block as measured by an EKG. (Phase Ib primary outcome) (NCT03102190)
Timeframe: 1-8 weeks

Intervention	Participants (Count of Participants)
Phase Ib	0

Diastolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-0.6
Control	1

Heart Rate

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements.

Intervention	beats per minute (Mean)
Treatment	-1.4
Control	4

Objective Sinonasal Symptoms on Lund-Kennedy Score(LKS)

Minimum Score: 0 Maximum Score: 12 Higher value represents worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-1.3
Control	-0.25

Objective Sinonasal Symptoms on Lund-McKay Score(LMS)

Minimum Score: 0 Maximum Score: 24 Higher value represents worse outcome. (NCT02454608)
Timeframe: Week 8

Intervention	units on a scale (Mean)
Treatment	12.5
Control	17.7

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-44.03
Control	-6.07

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 8

Intervention	units on a scale (Least Squares Mean)
Treatment	-27.3
Control	0.4

Systolic Blood Pressure

(NCT02454608)
Timeframe: Mean change between baseline and week 8 measurements

Intervention	mmHg (Mean)
Treatment	-4.5
Control	-6.6

Subjective Sinonasal Symptoms on 10cm Visual Analogue Scale(VAS)

Minimum Score: 0 Maximum Score: 100 A higher score indicates a worse outcome. (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	64.3	35.0	90.0	16.7

Subjective Sinonasal Symptoms on Sinonasal Outcomes Test-22(SNOT-22)

Minimum Score: 0 Maximum Score: 110 A higher score indicates a worse outcome (NCT02454608)
Timeframe: baseline to week 56

Intervention	units on a scale (Mean)
	Medicine Completers, baseline	Medicine Completers, week 56	Surgical Completers, baseline	Surgical Completers, week 12
Open Label	31.8	24.14	72.00	8.00

Other Studies

2 other studies available for verapamil and Eosinophilia

Article	Year
New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents. Journal of medicinal chemistry, 1999, Feb-25, Volume: 42, Issue:4 Topics: Acetylcholine; Animals; Anti-Allergic Agents; Bronchoalveolar Lavage; Capillary Permeability; Carbac	1999
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:2 Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An	2012
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:2 Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An	2012
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:2 Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An	2012
Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals. Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:2 Topics: Animals; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Calcium Channel Blockers; Disease Models, An	2012